Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an unprecedented event requiring frequent adaptation to changing clinical circumstances. Convalescent immune plasma (CIP) is a promising treatment that can be mobilized rapidly in a pandemic setting....

Descripción completa

Detalles Bibliográficos
Autores principales: Sturek, Jeffrey M., Thomas, Tania A., Gorham, James D., Sheppard, Chelsea A., Raymond, Allison H., Petros De Guex, Kristen, Harrington, William B., Barros, Andrew J., Madden, Gregory R., Alkabab, Yosra M., Lu, David Y., Liu, Qin, Poulter, Melinda D., Mathers, Amy J., Thakur, Archana, Schalk, Dana L., Kubicka, Ewa M., Lum, Lawrence G., Heysell, Scott K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865433/
https://www.ncbi.nlm.nih.gov/pubmed/35196802
http://dx.doi.org/10.1128/spectrum.02560-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865433/
https://www.ncbi.nlm.nih.gov/pubmed/35196802
http://dx.doi.org/10.1128/spectrum.02560-21

Ejemplares similares